AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
37.68
-0.04 (-0.11%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close37.72
Open37.46
Bid0.00 x 29200
Ask39.36 x 40700
Day's Range37.43 - 37.77
52 Week Range31.99 - 39.76
Volume1,705,160
Avg. Volume3,905,825
Market Cap92.87B
Beta0.50
PE Ratio (TTM)35.72
EPS (TTM)1.05
Earnings DateN/A
Forward Dividend & Yield1.40 (3.74%)
Ex-Dividend Date2018-08-09
1y Target Est41.66
Trade prices are not sourced from all markets
  • Reuters1 hour ago

    AstraZeneca CEO warns of medicine shortages after Brexit: Sunday Times

    Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times. The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely. Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW's lead and bringing forward its annual summer factory shutdown to coincide with Britain's departure from the EU in case there is no deal, but added no decision had been taken.

  • Reuters6 hours ago

    AstraZeneca ceo warns of medicine shortages after Brexit - Sunday Times

    Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times. The company said in July it would stockpile drugs as a Brexit safety net, and CEO Pascal Soriot told the Sunday Times in an interview that the complexity of the supply chain in pharmaceuticals meant that delays would be likely. Separately, the Sunday Times reported that Jaguar Land Rover was considering following BMW's lead and bringing forward its annual summer factory shutdown to coincide with Britain's departure from the EU in case there is no deal, but added no decision had been taken.

  • 3 High-Yield Stocks at Rock-Bottom Prices
    Motley Fool19 hours ago

    3 High-Yield Stocks at Rock-Bottom Prices

    Looking for big yield at a discount? These three could fit the bill.

  • NVS vs. AZN: Which Stock Is the Better Value Option?
    Zacks2 days ago

    NVS vs. AZN: Which Stock Is the Better Value Option?

    NVS vs. AZN: Which Stock Is the Better Value Option?

  • A Look at Shire’s Valuation on September 19
    Market Realist2 days ago

    A Look at Shire’s Valuation on September 19

    Shire (SHPG) is a biotechnology company focused on the discovery, development, and commercialization of specialized medicines for the treatment of rare diseases and other specialized conditions.

  • Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
    Zacks3 days ago

    Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

    In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

  • Reuters3 days ago

    FOCUS-AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON, Sept 19 (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters. Surrounded by the latest gizmos at the World Internet of Things Exposition in Wuxi, eastern China, Soriot says he wants to use the power of artificial intelligence, robots and apps to help transform diagnosis and disease management.

  • AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
    Zacks4 days ago

    AstraZeneca's Fasenra Long-Term Asthma Study Data Positive

    AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.

  • Reuters4 days ago

    Focus: AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.

  • AstraZeneca plots China robot offensive to counter price cuts
    Reuters4 days ago

    AstraZeneca plots China robot offensive to counter price cuts

    WUXI, China/LONDON (Reuters) - With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca (AZN.L) aims to move from simply supplying drugs to become a broad healthcare provider in China. Tech tie-ups with the likes of Alibaba (BABA.N) and Tencent will not directly lift the British group's drug sales, since they are not specific for any one company's products and in many cases will be low-cost or free. "Down the line we benefit, our products benefit, because we have better relationships with doctors and hospital managers and also because we diagnose more patients and they get better treated," Chief Executive Pascal Soriot told Reuters.

  • Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
    Zacks5 days ago

    Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

    Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

  • Business Wire5 days ago

    FASENRA (benralizumab) Shows Consistent Safety and Sustained Efficacy in Long-Term Phase III BORA Trial in Severe Eosinophilic Asthma

    AstraZeneca today announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of FASENRA™ (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed one of the two pivotal SIROCCO or CALIMA Phase III trials. In the BORA trial, FASENRA given for an additional 56 weeks showed a safety and tolerability profile similar to that observed in the placebo-controlled SIROCCO and CALIMA trials, with no increase in the frequencies of overall or serious adverse events.

  • AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale
    Bloomberg6 days ago

    AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale

    ADC Therapeutics SA, a Swiss biotechnology company whose backers include U.K. drugmaker AstraZeneca Plc, is in the early stages of exploring options including an initial public offering amid growing interest in innovative cancer treatments, according to people familiar with the matter. ADC is working with advisers at Morgan Stanley on a preliminary review, the people said, asking not to be identified because the deliberations are private. The Lausanne-based company -- which specializes in treatments that target cancer cells while sparing healthy ones -- is also considering a potential sale among the options, they said.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks9 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
    Zacks9 days ago

    AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia

    AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.

  • Johnson & Johnson Expands Blood Cancer Portfolio with Approval
    Market Realist9 days ago

    Johnson & Johnson Expands Blood Cancer Portfolio with Approval

    On August 27, Johnson & Johnson (JNJ) announced that it received FDA approval for its combination therapy of Imbruvica and Roche’s (RHHBY) rituximab for the treatment of WM (Waldenström’s macroglobulinemia), a rare blood cancer. According to JNJ, ~2,800 new WM cases are reported each year in the United States.

  • Business Wire9 days ago

    US FDA Approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell Leukemia

    Approval of LUMOXITI, a first-in-class medicine for hairy cell leukemia, marks first new treatment option for patients in over 20 years

  • Reuters9 days ago

    FDA approves AstraZeneca's drug for rare form of blood cancer

    The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc's treatment for hairy cell leukemia, a slow-growing type of blood cancer. The treatment, marketed as Lumoxiti, was approved for treating a stubborn form of the disease or a relapse in patients who have received at least two prior therapies, the FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620448.htm said. Lumoxiti includes a boxed warning advising health care professionals and patients about the risk of developing capillary leak syndrome, a condition in which fluid and proteins leak out of tiny blood vessels.

  • Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
    Zacks10 days ago

    Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study

    Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.

  • Motley Fool10 days ago

    3 Lung Cancer Stocks That Could End September on a High Note

    This year's World Conference on Lung Cancer has some important presentations scheduled.

  • InvestorPlace11 days ago

    The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger

    AstraZeneca’s (NYSE:AZN) profits look poised to resume growing, as a number of the drug company’s new treatments are expected to be approved by regulators. While ultimately the new drugs should compensate for the lost Crestor sales, it’s too early to say when the positive outlook will be reflected in AZN stock. If these forecasts hold, and AZN stock can trade consistently above $40 per share, AstraZeneca stock could finally rally.

  • Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus
    Zacks11 days ago

    Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus

    Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.

  • The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson
    Zacks13 days ago

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

  • Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus
    Zacks16 days ago

    Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

    Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

  • AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status
    Zacks16 days ago

    AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status

    AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.